Oculox Technologies SA: Company Research Report

Company Overview

• Name: Oculox Technologies SA

• Mission: To drive innovation in ophthalmology and revolutionize treatment options for eye diseases by redefining standards of care and ensuring a brighter future for all.

• Year Founded: No information is available

• Founders: No information is available

• Key People:

• Filippo Piffaretti, Chief Executive Officer

• Samuel Dini, Chief Financial Officer

• Martial Geiser, Chief Science Officer

• Francesco Dell'Antonio, Chief Compliance Officer

• Sébastien Buchwalder, Chief Business Officer

• Diego Vezzola, Chief Medical Officer

• Headquarters: Via Industria 3, CH-6933 Muzzano, Switzerland

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: Developing medical devices and advancing technology in ophthalmology, particularly in creating platforms that integrate diagnostics and treatment solutions for eye diseases.

Products

WISE

• Description: An innovative device utilizing advanced opto-perceptive principles to evaluate retinal functions and support early diagnosis of eye disorders.

• Key Features:

• Objective Eye Evaluation: Uses metamerism and silent substitution techniques.

• Tailored Bilateral Assessments: Uses Maxwellian optical arrangement for accurate measurements.

• Tailor-Made Protocols: Allows for customization of eye stimuli.

• Regulatory Compliance: CE-marked Class I medical device.

• Ease of Use: Ergonomically designed for patient and clinician comfort.

SEES

• Description: A therapeutic device using innovative light combination therapy to treat intermediate age-related macular degeneration (AMD).

• Key Features:

• Multi-Mode Light Stimulation: Promotes retina-tissue homeostasis.

• Standardized Therapeutic Parameters: Ensures effective treatment outcomes.

• Dosimetry: Enables real-time evaluation and personalized treatment dosimetry.

• Compact and Intuitive Design: Non-invasive and comfortable for patients.

• Real-Time Retina Alignment Monitoring: Provides safe and homogeneous treatment sessions.

Recent Developments

• New Products Launched: No specific new product launches mentioned beyond WISE and SEES.

• New Features Added to Existing Products: No information is available

• Partnerships: Close collaborations with ophthalmologists in different clinical settings and partnerships with professionals in various disciplines are emphasized.

• Other Developments: No other specific recent developments are highlighted. However, the company is continuously involved in advancing their therapeutic platform and conducting validation clinical trials for SEES.

This comprehensive report on Oculox Technologies SA outlines key details about the company and its commitment to pioneering innovation in the field of ophthalmology. The information provided presents a snapshot of their leading-edge products designed to enhance eye care and treatment methodologies.